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The presymptomatic phase of neurodegenerative diseases are characterized by structural brain changes
without signiﬁcant clinical features. We set out to investigate the contribution of functional network
resilience to preserved cognition in presymptomatic genetic frontotemporal dementia. We studied 172
people from families carrying genetic abnormalities in C9orf72, MAPT, or PGRN. Networks were
extracted from functional MRI data and assessed using graph theoretical analysis. We found that despite
loss of both brain volume and functional connections, there is maintenance of an efﬁcient topological
organization of the brain’s functional network in the years leading up to the estimated age of fronto-
temporal dementia symptom onset. After this point, functional network efﬁciency declines markedly.
Reduction in connectedness was most marked in highly connected hub regions. Measures of topological
efﬁciency of the brain’s functional network and organization predicted cognitive dysfunction in domains
related to symptomatic frontotemporal dementia and connectivity correlated with brain volume loss in
frontotemporal dementia. We propose that maintaining the efﬁcient organization of the brain’s func-
tional network supports cognitive health even as atrophy and connectivity decline presymptomatically.
 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).l Neurosciences, Cambridge
n Way, Cambridge CB2 0SZ,
an).
nc. This is an open access article un1. Introduction
Many neurodegenerative dementias begin their neuropathology
years or even decades before the onset of symptoms. The evidence
of presymptomatic pathology comes from changes in structuralder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pathological proteins, and abnormal cerebrospinal ﬂuid and blood
biomarkers (Jack Jr et al., 2010; Ridha et al., 2006; Rohrer et al.,
2015). However, it is not clear why people with signiﬁcant pro-
gressive neurodegeneration and brain volume loss remain free of
symptoms for so long or develop symptoms when they do. To
address this issue, we assessed functional network resilience in the
Genetic Frontotemporal Dementia Initiative (GENFI) cohort.
Network resilience derives from the robust and efﬁcient
arrangement of connections between brain regions (Bullmore and
Sporns, 2012). This arrangement is characterized by the presence
of highly connected hubs (Power et al., 2013; Tomasi and Volkow,
2011) in a “small world” arrangement which minimizes the topo-
logical distance (also called path length) between parts of the
network. This path length can be used to derive measures of global
or regional network efﬁciency. Networks that have an efﬁcient
small-world topology are intrinsically robust to processes that
damage the network by removing network nodes or connections.
Examining the network organization of the brain has provided
critical insights into neurocognitive development and diverse disor-
ders of the nervous system from multiple sclerosis (Hawellek et al.,
2011; Rocca et al., 2014), depression (Greicius et al., 2007), schizo-
phrenia (Fornito et al., 2012), and autism (Moseley et al., 2015) to
multiple neurodegenerative diseases including frontotemporal de-
mentia (FTD) (Filippi et al., 2013; Seeley et al., 2007; Zhou et al., 2010);
Alzheimer’s disease, Parkinson’s disease (Luo et al., 2014; Rittman
et al., 2016); and Progressive Supranuclear Palsy (Rittman et al.,
2016; Whitwell et al., 2011). In patients, altered network connectiv-
ity is consistently associated with the loss of cognitive function (Day
et al., 2013; Pievani et al., 2011) or reduced response to treatment
(Lui et al., 2011; Ye et al., 2016). In contrast, here we assess whether
network integration provides resilience at earlier stages of the disease
process, with the maintenance of cognitive well-being, even in the
presence of established neuropathology and brain atrophy. To bemore
speciﬁc, we assess functional network resilience, which is deﬁned as
the maintenance of the topological properties of a functional brain
network in the context of structural changes to the brain.
We identiﬁed functional brain networks from functional MRI
(fMRI) images, using the blood oxygen leveledependent effect as an
indirect measure of neural activity. The advent of task-free fMRI
(also called “resting state” fMRI) (Biswal et al., 1997) has facilitated
the analysis of brain function in severely impaired clinical groups
while retaining a strong relationship to functionally deﬁned brain
networks. The connectome (Sporns, 2011) derived from task-free
fMRI is robust, reproducible, and capable of generating brain net-
works analogous to other physiological techniques such as EEG or
magnetoencephalography (Brookes et al., 2011).
We used task-free fMRI to assess people with genetic FTD and
their ﬁrst-degree relatives in whom approximately half carry the
familial gene abnormality. Our cohort included mutations or ex-
pansions in the three major genes associated with FTD: PGRN,
MAPT, C9orf72. We tested the hypothesis that before the age of
symptom onset in genetic FTD, functional network resilience arises
from the maintenance of an efﬁcient network topology preserving
cognitive function in the context of progressive pathology assessed
by brain volume loss. From the age of symptom onset, we would
expect the loss of functional network resilience, with a decline in
network efﬁciency and connectivity in relation to both brain vol-
ume loss and cognitive function.
2. Materials and methods
Subjects were recruited as part of the multicenter international
GENFI and underwent a standardized assessment (Rohrer et al., 2015).
The age of expected symptom onset was deﬁned as the mean withineach family, which is signiﬁcantly correlated among affected relatives
(Rohrer et al., 2015). Echo-Planar Imaging andMagnetization Prepared
Rapid Gradient Echo (MPRAGE) were acquired at each center. Analo-
gous imaging sequences were acquired at each GENFI study site ac-
commodating different manufacturers and ﬁeld strengths (1.5 T and
3T). Echo-planar images were acquired over at least 300 s with a
median of 315 s (inter-quartile range 309e440) and had a median
repetition time of 2200 ms (2200 mse3000 ms), echo time of 30 ms,
in-plane resolution of 2.75  2.75 mm (2.75e3.31  2.75e3.31), and
slice thickness of 3.3 mm (3.0e3.3). MPRAGE images were obtained
during the same acquisition.
Image preprocessing used MPRAGE images to generate a trans-
formation to register images to Montreal Neurological Institute
standard space via a study-speciﬁc template using Diffeomorphic
Anatomical Registration Through Exponentiated Lie algebra imple-
mented in SPM12 (www.ﬁl.ion.ucl.ac.uk/spm/software/spm12/).
This transformation was applied to coregistered functional images.
Functional image pre-processing was performed using the brain-
wavelet pipeline (www.brainwavelet.org) including slice-time
correction, regression of cerebrospinal ﬂuid, white matter, move-
ment parameters and their derivatives, and despiking using a
wavelet algorithm. Identiﬁcation of motion outliers for exclusion
used the spike percentage threshold, deﬁned as the percentage of the
time series in which spikes were identiﬁed during the wavelet des-
piking process. The spike percentage threshold was set at 10% at
which level the removal of subjects did not signiﬁcantly change the
connection strength measured across all subjects.
Each subject’s brain volume was parcellated into 500 approxi-
mately equally sized regions using a centroidal Voronoi tessalation
(Du et al., 1999). Of the 500 regions, 29 were insufﬁciently covered
in some or all subjects, leaving 471 regions for further analysis. The
fMRI signal time series within each parcel was bandpass ﬁltered
using a wavelet scale of 0.0675e0.125 Hz.
Graph theoretical analysis was applied to network connectivity;
the wavelet cross-correlationwas used as a measure of the strength
of each connection. Networks were then analyzed in terms of
connection strength, efﬁciency, and connectedness. Graph analysis
used the Maybrain package (github.com/RittmanResearch/may-
brain). We deﬁned connection strength as the sum of nodal
connection strength (also called weighted degree) values of all the
network’s nodes. To capture the property of network efﬁciency, we
use measures based on path length. The global efﬁciency is deﬁned
as the sum of the inverse path lengths for all nodes in a network.
The analogous nodal measure of closeness centrality is deﬁned as
the sum of the path lengths for each node to all other network
nodes. Efﬁciency measures were normalized against the mean
value generated from 500 graphs with an identical degree distri-
bution and random connections. We assessed atrophy by calcu-
lating the percentage brain volume or regional volume compared
with the total intracranial volume. Hubs were deﬁned in the gene-
negative group as brain regions with connection strength two
standard deviations greater than other regions.
Because network measures are not independent, we did not
apply correction for multiple comparisons. Group comparisons
between the gene carrier and FTD group were performed for each
network measure using a mixed-effects linear model with diag-
nostic group as the main effect, age as a dependent variable, and
scan site and gene type as randomvariables using the lmer package
in R. We included the gene-negative group in all models to properly
estimate the effect of age. We then assessed group differences by
specifying an appropriate contrast between the gene carrier group
and FTD groups. The Satterthwaite estimate of effective degrees of
freedom enabled calculation of signiﬁcance values. To assess the
relationship between estimated age at onset and network mea-
sures, we extended the linear mixed-effects model by including an
Table 1
Demographics for subjects included in the analysis
Demographic p Value Gene negative Gene carriers FTD
Age, y (SD) <0.00001 47.8 (15.5) 44.5 (12.3) 62.4 (8.6)
Sex (M/F) nsa 49(61%)/31(39%) 40(59%)/28(41%) 7(29%)/17(71%)
Hand (L/R/Ambi) ns 74(93%)/5(6%)/1 (1%) 58(85%)/8(12%)/2 (3%) 22(92%)/2(8%)/0 (0%)
Education, y (SD) ns 13.7 (3.5) 13.8 (3.2) 12.2 (4.5)
For parametric data, analysis of variance was used and we report the mean, and the standard deviation in parentheses.
For categorical data, the c2 test was used and we report the numbers in each category.
As expected, people with FTD were older than both gene carriers (p < 0.00001) and gene-negative subjects (p < 0.00001).
Key: FTD, frontotemporal dementia; ns, non-signiﬁcant >0.1; SD, standard deviation.
a Although sex differences were not signiﬁcant when tested across all three groups, pairwise tests conﬁrmed that there were fewer men in the FTD patient group compared
with both the gene carrier (p ¼ 0.02) and gene-negative (p ¼ 0.01) groups.
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to symptom onset.
3. Results
Twenty-nine people with genetic FTD were recruited (12
C9orf72, 11 MAPT, 6 PGRN), 70 unaffected relatives carrying the
same mutation we will refer to as “gene carriers” (17 C9orf72, 13
MAPT, 40 PGRN) and 86 relatives without the mutation referred to
as “gene negative.” During image processing, 13 subjects were
removed because of excessive motion, 5 with FTD (1 C9orf72, 2
MAPT, 2 PGRN), 2 gene carriers (2 PGRN), and 6 gene negative. The
remaining 172 subjects were taken forward for analysis: 24 FTD, 68
gene carriers, and 80 gene negative. Demographic information is
shown in Table 1. The FTD clinical syndromes were behavioral
variant FTD n ¼ 20, FTD-motor neuron disease n ¼ 1, primary
progressive aphasia n ¼ 2, dementia not otherwise speciﬁed ¼ 1.
3.1. Differences in network connectivity and efﬁciency between
groups
To assess the difference in global network properties between
the gene negative, gene carriers, and FTD groups, brain networksFig. 1. Connection strength is reduced in genetic FTD compared to asymptomatic geneecar
carrying relatives demonstrate reduced connection strength using a mixed-effects linear mo
genes are shown for completeness, although we would be cautious in interpreting these res
connection strength in the PGRN FTD group (p < 0.00001) and global efﬁciency in the MAP
network measures and time to the estimated age of symptom onset, we performed disconti
0.009) but not for connection strength (p ¼ 0.9). Signiﬁcance values: *<0.05, **<0.01, ***<0were assessed for connection strength and global efﬁciency, shown
in Fig. 1. The FTD group (mean connection strength 121.8) was less
well connected compared with gene carrier (149.4, p ¼ 0.01) and
gene-negative groups (147.1, p ¼ 0.02). Gene carriers (mean global
efﬁciency 0.88) had a higher global efﬁciency than the gene-
negative group (0.86, p ¼ 0.004), but there was no differences in
global efﬁciency in any other comparison (FTD 0.86). We found
similar regional reduction in connectivity in frontal lobes, temporal
lobes, occipital lobes, and cingulate cortices, cerebellum, and insula
cortices in the FTD group compared with gene carriers; increased
efﬁciency (closeness centrality) in all brain regions in the gene
carrier group compared with the gene-negative group and reduced
efﬁciency in the occipital cortex in FTD compared with gene car-
riers; see Figs. 2 and 3 and eTable 1.
To assess whether regional network properties would inﬂuence
change in network properties, we examined the most highly con-
nected “hub” regions. By deﬁnition, hubs were more connected
than nonhubs; however, the difference in connection strength be-
tween hubs and nonhubs was signiﬁcantly smaller in the FTD group
(p ¼ 0.02), suggesting that hubs were weaker in the FTD group. The
difference in efﬁciency measured by closeness centrality between
hubs and nonhubs was abolished in the FTD group (effect size
0.0025, p ¼ 0.5) compared with gene carriers (effect size 0.01, p <rying relatives. Differences between the genetic FTD group and presymptomatic-gene
del (p ¼ 0.01) with no difference in global efﬁciency (p ¼ 0.2). The results for individual
ults, given the small group sizes. Using a simple t-test, there was signiﬁcantly reduced
T FTD group (p ¼ 0.02). To assess whether there was a nonlinear relationship between
nuous breakpoint analysis. There was a signiﬁcant breakpoint in global efﬁciency (p ¼
.001. FTD, frontotemporal dementia.
Fig. 2. Although relevant brain regions demonstrate reduced connectivity in FTD, there is no signiﬁcant change at symptom onset. For each brain region, the difference in
connection strength between gene carrier and FTD groups is presented; signiﬁcant values were calculated using a mixed-effects linear regression model. There were signiﬁcant
differences in the frontal, temporal, occipital, cingulate, and insula cortices (see eResults). However, no brain region demonstrated a signiﬁcant breakpoint in connect strength at the
age of symptom onset (using a piecewise linear regression model). Signiﬁcance values: *<0.05, **<0.01, ***<0.001. FTD, frontotemporal dementia.
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(p ¼ 0.001).
3.2. Disease progression and network measures
To test the relationship between networkmeasures and disease
progression, we began by estimating the temporal relationships
between network measures and symptom onset. There were no
simple linear relationships of time to the estimated age of symp-
tom onset with connection strength (p ¼ 0.6) or global efﬁciency
(p ¼ 0.17).We then tested whether there may be a nonlinear decline in
network properties. We assessed whether a breakpoint existed in
the relationship between estimated time to symptom onset and
network measures at the estimated time of symptom onset using
piecewise regression analysis. There was no signiﬁcant breakpoint
in network measures at the estimated time of onset in connection
strength for the whole brain (p ¼ 0.9) or any brain region, see Fig. 2
and eResults. For global efﬁciency, we found a signiﬁcant break-
point (p ¼ 0.009) suggesting that global efﬁciency starts to decline
at the time of symptom onset, see Fig.1. We saw similar breakpoints
for efﬁciency in the frontal lobes, parietal lobes, occipital lobes, and
Fig. 3. Brain regions demonstrate both reduced efﬁciency in FTD and a signiﬁcant decline in efﬁciency beginning at symptom onset. For each brain region, the difference in
closeness centrality between gene carrier and FTD groups are presented; signiﬁcant values were calculated using a mixed-effects linear regression model (see eResults). There were
signiﬁcant differences in the frontal, temporal, occipital, cerebellar, and cingulate cortices. In contrast to the connectivity results, there were signiﬁcant breakpoints in closeness
centrality at the age of symptom onset in frontal, temporal, parietal, occipital, and cingulate cortices. These ﬁndings suggest that an efﬁcient brain structure is maintained in these
brain regions up to the time that symptoms of FTD emerge but that the efﬁcient structure rapidly breaks down thereafter. Signiﬁcance values: *<0.05, ** <0.01. FTD, frontotemporal
dementia.
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network topology declines in a dramatic fashion at the point of
transition from presympomatic to symptomatic FTD.
3.3. Functional network resilience to brain atrophy
We assessed whether connection strength and network efﬁ-
ciency was associated with brain volume loss, see Fig. 4. Connection
strength correlated with reduced brain volume in the FTD group(r ¼ 0.47, p ¼ 0.0002). This correlation differed signiﬁcantly from
the nonsigniﬁcant relationship between connection strength in the
gene carrier group (r ¼ 0.031, p ¼ 0.6), difference between in-
teractions (p ¼ 0.001). Similar differences were seen in the frontal,
temporal, and parietal lobes; see Fig. 4 and eResults.
There was no relationship between global efﬁciency in the FTD
group and whole-brain atrophy (p ¼ 0.2), and no interaction be-
tween the FTD group and gene carriers on the relationship between
global efﬁciency and whole-brain atrophy (p ¼ 0.3). No brain
Fig. 4. Whole-brain atrophy and the atrophy in relevant brain regions are correlated with the loss of connectivity only after symptom onset. We examined whether the volume of
the whole brain and brain regions was associated with loss of connection strength. There was a relationship between volume and connection strength in the whole brain (p ¼
0.0002), frontal lobe (p ¼ 0.005), and temporal lobes (p < 0.00001) in the FTD group only and not in the gene carrier group; in each case, there was a signiﬁcant difference between
the relationship in the FTD group and gene carrier groups (whole-brain p ¼ 0.001; frontal lobes p ¼ 0.02; temporal lobes p ¼ 0.0002). Signiﬁcance values: **<0.01, ***<0.001,
****<0.0001. FTD, frontotemporal dementia.
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whole-brain or regional atrophy.
3.4. Relationship between network properties and cognitive
function
Clinical scores are shown in Table 2. As expected, there were no
signiﬁcant differences between gene-negative and gene carrier
groups, whereas all measures were markedly impaired in the FTD
group compared with the gene carrier group (p < 0.0001 for all
comparisons). The relationship between clinical test scores and
years from expected onset was not clearly linear in the FTD group,
suggestive of an acute decline in ability at diagnosis rather than a
continuous linear association.
We found strong relationships in the FTD group of connection
strength with both Mini-Mental State Examination (MMSE; p ¼
0.002) and trails A (p¼ 0.0002) and a difference in the relationships
between the FTD and gene carrier groups for both cognitive mea-
sures (MMSE: p ¼ 0.004, trails A: p ¼ 0.0006), although there were
possible ceiling effects in the gene carrier group on both these tests,
see eTable 2 for full results.
For digit span and verbal ﬂuency, we observed a relationship
between connection strength and test performance across both FTD
and gene carrier group combined, but no difference in the rela-
tionship between groups: digit span (p ¼ 0.03), categorical verbal
ﬂuency (p¼ 0.03), and letter verbal ﬂuency (p¼ 0.01). This suggests
that a loss of connectivity before the onset of clinical symptoms is
relevant to declining cognitive performance in these tests. Of note,we included age as a covariate in these models, to reduce the
likelihood that age explained these results.
Higher global efﬁciency was associated with better performance
on theMMSE in the gene carrier group (p< 0.001), but therewas no
such relationship in the FTD group (p¼ 0.053); the difference in the
effect between groups was signiﬁcant (p ¼ 0.049). There was a
decline in performance on Trails B with reduced global efﬁciency in
the FTD group (p ¼ 0.02), although the difference in this relation-
ship from the gene carrier group did not reach signiﬁcance (p¼ 0.1).
There was no other signiﬁcant relationship between global efﬁ-
ciency and cognitive performance.
Finally, we tested whether region-speciﬁc measures might
correlate with cognitive scores, shown in eTable 2. Both MMSE and
Trials A demonstrated consistent relationships with connection
strength in FTD and signiﬁcant difference from the gene carrier
group (occipital lobe, temporal lobe, insula, cingulate, hippocam-
pus) similar to the whole-brain results. However, these tests
demonstrate marked ceiling effects, which may limit the interpre-
tation of these results.
Worse performance on forward digit spanwas related to a loss of
connection strength in the parietal lobe in FTD and in the Boston
naming test with loss of connection strength in the occipital lobe.
Both these relationships differed signiﬁcantly from the gene carrier
group; see eTable 2.
For the network efﬁciency measure of closeness centrality, the
Trials B test that requires signiﬁcant working memory was related
to network efﬁciency in the hippocampus, and this relationship
differed signiﬁcantly from the gene carrier group; see eTable 2.
Table 2
Mean clinical scores for each group with standard deviation shown in parentheses
Gene negative Gene carriers FTD
MMSE 29.2 (1.4) 29.1 (1.5) 22.3 (6.3)
Log immediate memory 0.08 (1.02) 0.08 (0.84) 2.07 (1.1)
Log delayed memory 0.08 (0.98) 0.04 (0.77) 2.08 (0.99)
Forward digit span 0.02 (0.97) 0.03 (1) 1.21 (1.44)
Backwards digit span 0.01 (0.99) 0.12 (0.9) 1.71 (1.19)
Trails A 0.2 (0.91) 0.29 (0.58) 2.49 (2.49)
Trails B 0.16 (0.91) 0.24 (0.88) 2.49 (1.34)
Digit symbol task 0.25 (1.12) 0.27 (0.95) 1.98 (0.89)
Boston Naming Task 0.15 (0.88) 0.03 (1.1) 3.53 (2.66)
Verbal ﬂuency (Category) 0.14 (1.02) 0.16 (0.91) 2.04 (0.9)
Verbal ﬂuency (Letter) 0.06 (1.01) 0.05 (1.2) 2.64 (0.96)
Block design task 0.01 (1) 0.17 (0.98) 2.05 (0.97)
The raw MMSE score is shown and z-score for other measures.
These scores are corrected for language but not for other demographics.
Key: FTD, frontotemporal dementia.
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efﬁciency and MMSE score, and a signiﬁcant difference in this
relationship compared with the gene carrier group in the occipital
lobe, cerebellum, and insula.
Taken together, the correlations with cognitive scores suggest
that changes to speciﬁc brain regions of connection strength and
efﬁciency may be relevant to speciﬁc cognitive functions, particu-
larly in the Trails B, forward digit span, and Boston naming tasks.
4. Discussion
We demonstrate that the brain can function normally for
cognitive well-being despite substantial presymptomatic neuro-
degenerative disease if it can maintain efﬁcient information pro-
cessing through functional connections, but that brain network
efﬁciency declines sharply around the time of symptom onset. The
loss of network efﬁciency is most severe in highly connected hub
regions, and regional changes in network efﬁciency are associated
with worsening of cognitive deﬁcits associated with FTD. We pro-
pose that interventions during the crucial presymptomatic period
of neurodegenerative disease could be effective if they promote the
maintenance or resilience of the brain’s intrinsically efﬁcient
arrangement of functional network connections.
Our ﬁndings challenge the concept that functional deﬁcits
mirror structural change early in the disease process. This is not to
say that structural changes are irrelevant to brain function (Jack Jr
et al., 2004, 2009). However, many years before symptom onset,
there can be gross changes in brain structure and cerebrospinal
ﬂuid biomarkers that indicate an active neuropathological pro-
cesses and atrophy, both in familial neurodegenerative disease
(Dopper et al., 2013; Ridha et al., 2006; Rohrer et al., 2015; Schott
et al., 2003) and in sporadic disease such as early Alzheimer’s dis-
ease and MCI (Liu et al., 2010; Olsson et al., 2016; Yao et al., 2010).
We therefore tested whether resilience of brain network organi-
zation can explain the discrepancy between changes in structure
and cognitive function.
The brain’s resilience to structural change in presymptomatic
disease might depend on topological resilience or active compen-
sation. We propose that topological resilience provides a greater
contribution for several reasons. In common with many ecological
and man-made networks, the brain’s network has a “small-world”
conﬁguration that balances the metabolic costs of long-distance
connections between any two points in the network (path length)
and shared connections between locally connected nodes (clus-
tering) (Achard and Bullmore, 2007; Achard et al., 2006; Vértes
et al., 2012). Highly connected hubs are essential to small-world
networks. In the brain, they are metabolically active (Achardet al., 2012; Buckner et al., 2009) and play a role in efﬁcient inte-
gration of information between regions (Power et al., 2013;
Sepulcre et al., 2013; Sporns et al., 2007; Tomasi and Volkow,
2011). The presence of hubs means that small-world networks are
resilient to targeted and random network attacks even if the hubs
themselves are more prone to the effects of neuropathology.
The concept of functional network resilience is closely linked
and overlapping with the concepts of cognitive reserve, brain
reserve, and brainmaintenance (Stern et al., 2018). Our deﬁnition of
functional resilience is closely alignedwith cognitive reserve, which
is a multifaceted concept positing that educational, social, and ex-
ercise lead to maintained cognitive abilities in the context of aging
or neurodegeneration (Cabeza et al., 2018). There is preliminary
evidence that cognitive reserve (at least as estimated from aca-
demic and occupational attainments) ameliorates the cognitive
impact of neurodegenerative disease or against reaching the
threshold for diagnosis of neurodegenerative disease (Stern, 2009;
Wu et al., 2016). Indeed, higher cognitive reserve (estimated by
years of education) is associated with slower atrophy and later
symptom onset in familial FTD associated with TAR DNA-binding
protein 43 (Premi et al., 2017). This effect is moderated by genetic
factors (TMEM106B genotype), with many questions remaining as
to the mechanisms of effect of cognitive reserve. It is likely that
functional brain imaging reﬂects aspects of cognitive reserve (Solé-
Padullés et al., 2009), but these are not yet well established. It is
beyond the scope of this study to identify the effect of education on
functional network resilience or the genetic moderators of such an
effect. As a cross-section study, possible cohort effects mean that
differences in cognitive reserve between younger and older gene
carriers cannot wholly be ruled out as a contributor to the main-
tenance of global efﬁciency we observe. However, the stability of
global efﬁciency in the years leading up to symptom onset (Fig. 1)
averages across subjects with differences in education and occu-
pation reserve at any given range of years from expected onset of
symptoms.
We found a complex relationship between functional connec-
tivity and brain volume loss. In the FTD group, a relatively small
reduction in connection strength was correlated with a much
greater reduction in brain volume, which was not the case in pre-
symptomatic or gene-negative participants. One intriguing possi-
bility is that premorbid connection strength inﬂuences the rate of
volume loss in disease. This echoes previous studies showing that
speciﬁc brain network and connectivity patterns inﬂuence the
pattern of brain atrophy and neuropathology in a range of neuro-
degenerative diseases (Cope et al., 2018; Seeley et al., 2009).
We assessed whether clinical measures of disease would help us
to relate domains of cognitive function to the changes we observed
in functional network resilience. In general, the associations were
not strong, which may relate to the global nature of the network
measures we assessed in comparison to the more speciﬁc and
localizable clinical measures. However, we identiﬁed a decline in
verbal ﬂuency in relation to connection strength that may reﬂect
subtle presymptomatic cognitive impairment. We found relation-
ships between local measures of network connectivity with the
Boston naming test in the occipital lobe and digit span in the pa-
rietal lobe. We are cautious about interpreting these results, given
the relatively weak associations and the seeming mismatch in
localization. It is likely that more local or network-speciﬁcmeasures
of network integrity would be better associated with cognitive
tests.
Our study has several important limitations. Cohorts of genetic
dementia are rare and despite a coordinated multinational
recruitment effort, the number of subjects is relatively small,
although larger than many comparable studies of functional neu-
roimaging in dementia. This study was cross-sectional rather than
T. Rittman et al. / Neurobiology of Aging 77 (2019) 169e177176longitudinal; therefore, our inference of change over time is based
on the assumption of a similar starting value and rate of change
between individuals. fMRI has been often open to criticism as a
technique because it measures an indirect measure of blood oxygen
leveledependent effect as a surrogate for neuronal activity
(Tsvetanov et al., 2015); it has a poor frequency resolution, and it
may be affected by movement of subjects within the scanner.
Despite these limitations, it has proven to be a valuable and useful
tool to interrogate brain networks and produces network data
comparable to other techniques such as EEG or MEG. There were
more females in the FTD group compared to males, although
comparison across the three groups (gene negative, carriers, and
FTD) was not signiﬁcant. While a more balanced cohort would be
ideal, we consider that the effects of FTD would outweigh any
subtle gender effects, and gender differences would not explain the
differences between gene carriers and gene-negative participants.
5. Conclusions
We propose that the maintenance of functional brain networks
underlies the resilience of the brain to neurodegenerative pa-
thology in the presence of signiﬁcant neuronal loss. We suggest
that resilient topological organization rather than active
compensation is the main contributor to this resilience. Our
ﬁndings suggest a window of opportunity to intervene in the
presymptomatic stage of neurodegenerative diseases, including
treatment strategies that promote efﬁciency and integration in the
brain’s functional brain networks even in the presence of pro-
gressive atrophy.
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